Trial Profile
Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- 11 Dec 2020 Planned primary completion date changed from 30 Nov 2020 to 30 Mar 2021.
- 11 Dec 2020 Status changed from not yet recruiting to recruiting.
- 26 Sep 2018 Trial design of the study presented at the 19th World Conference on Lung Cancer.